Ozempic not tied to pancreatic cancer risk, study suggests

Ozempic and other glucagon-like peptide-1 receptor agonists are not linked to a higher risk of pancreatic cancer compared to insulin, according to a recent study.

GLP-1s approved for Type 2 diabetes, including Ozempic, Trulicity and Rybelsus, have faced regulatory scrutiny for a range of side effects such as hair loss, aspiration and suicidal thoughts. A potential connection between GLP-1s and pancreatic cancer, though, was suggested to be unfounded in an Israel-based study of more than 500,000 adult patients.